People · Operator
Named in public records as an officer, director or promoter · active 2011–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Heron Therapeutics, Inc. /De/ | — | Biotechnology | Series C | $117.2M | $382.4M | 2011 |
KEVIN C. TANG at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside KEVIN C. TANG on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| CRAIG JOHNSON | 1 | 16 |
| Robert Zerbe | 1 | 5 |
| Paul Goddard | 1 | 4 |
| John Barr | 1 | 3 |
| Kevin Tang | 1 | 3 |
| Kevin Kotler | 1 | 3 |
| Christian Waage | 1 | 2 |
| John Whelan | 1 | 2 |
| Gregory Turnbull | 1 | 2 |
| JOHN B. WHELAN | 1 | 2 |
| Craig Collard | 1 | 2 |
| BARRY D. QUART | 1 | 2 |
| Adam Morgan | 1 | 1 |
| Susan Rodriguez | 1 | 1 |
| GREGORY C. TURNBULL | 1 | 1 |
| JOHN A. BARR | 1 | 1 |
| PAUL A. GODDARD | 1 | 1 |
| MICHAEL A. ADAM | 1 | 1 |
| Ronald Prentki | 1 | 1 |
| Toby Rosenblatt | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.